Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD5423 · 3 trials · 3 indications
LAR was assessed on Day 6 as minimum percentage of FEV1 over 3 to 7 hours based on the analysis of the minimum percentage of FEV1 remaining over 3 to 7 hours post allergen challenge (post AC) compared to pre allergen challenge (pre AC) FEV1
| Arm | Type | Description |
|---|---|---|
| AZD5423 | EXPERIMENTAL | New study drug |
| Budesonide | ACTIVE_COMPARATOR | Comparator to which the new study drug will be compared |
| Placebo | PLACEBO_COMPARATOR | No drug to which both other arms will be compared |
| 1 | EXPERIMENTAL | AZD5423 75ug |
| 2 | EXPERIMENTAL | AZD5423 300ug |
| 3 | ACTIVE_COMPARATOR | Budesonide 200 microgram |
| 4 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| AZD5423 | DRUG | oral inhaled |
| Budesonide | DRUG | oral inhaled |
| Placebo | DRUG | oral inhaled |
| Budesonide 200 microgram | DRUG | Dry powder for inhalation twice daily 7 days |
Inclusion Criteria: * Provision of signed and dated informed consent prior to conducting any study specific procedures * Men or women aged ≥ 40 years * Men or post-menopausal or surgically sterile women. Women will be considered post-menopausal if they have been amenorrheic for at least 12 months, ...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
AZD5423 is an investigational small molecule drug developed by AstraZeneca PLC for respiratory conditions, specifically asthma and chronic obstructive pulmonary disease (COPD). It is a modulator of NR3C1, also known as the glucocorticoid receptor. AZD5423 has completed Phase 2 clinical trials and has not been approved for any indication.
AZD5423 was studied for the treatment of asthma and chronic obstructive pulmonary disease (COPD). In COPD, it was evaluated in patients receiving background therapy with formoterol. In asthma, it was tested in patients with mild asthma challenged with an inhaled allergen. The drug remains investigational and is not approved for these or any other uses.
AZD5423 targets NR3C1, the glucocorticoid receptor. It is classified as a modulator of this receptor. By interacting with NR3C1, AZD5423 is designed to modulate glucocorticoid receptor activity, which is relevant to inflammatory respiratory conditions such as asthma and COPD. The drug is a small molecule administered via inhalation in clinical studies.
AstraZeneca PLC, which trades under the ticker AZN, is the developer of AZD5423. The company sponsored the clinical trials evaluating the drug in asthma and COPD. AstraZeneca is a global biopharmaceutical company headquartered in the United Kingdom.
AZD5423 has completed Phase 2 clinical development. Two Phase 2 trials and one Phase 1 trial have been completed, with no active trials ongoing. The drug is investigational and has not received FDA approval. It was studied in a total of 353 participants across the Phase 2 COPD trial and smaller asthma studies.
AZD5423 has been evaluated in completed trials including NCT01555099, a Phase 2 study in COPD patients on formoterol background therapy with 353 participants across multiple European countries. NCT01225549 was a Phase 2 allergen challenge study in mild asthma with 27 patients in Canada. NCT01310322 was a Phase 1 pharmacokinetic study in healthy subjects and mild asthmatics in the United Kingdom.